AIM ImmunoTech Announces Q3 2023 Financial Results Conference Call for November 15, 2023

OCALA, Fla., Nov. 09, 2023 -- AIM ImmunoTech Inc. AIM, a leading immuno-pharma corporation, has today communicated its plans to host an informative conference call as well as a webcast to candidly discuss the company's operational and financial outcomes for the third quarter of the year 2023. This eagerly awaited event is scheduled for Wednesday, November 15, 2023, at 8:30 AM Eastern Time. The call promises to offer valuable insights into the company’s recent developments and financial health.

Participation Details and Access Information

The upcoming conference call will feature contributions from distinguished members of AIM’s leadership, namely Thomas K. Equels, Chief Executive Officer, and Christopher McAleer, Ph.D., Scientific Officer. Stakeholders, including participants and investors looking to access the call, can do so by dialing (877) 407-9219 for domestic calls or (201) 689-8852 for international calls. The reference to be used is the AIM ImmunoTech Conference Call. Moreover, the webcast will be conveniently accessible on the Events page, located in the Investors section of AIM’s website, aimimmuno.com. The webcast also is planned to be archived and available for replay for a duration of 90 days following the live presentation.

Company Profile

AIM ImmunoTech Inc. is a company devoted to the pursuit of innovative therapies aimed at the treatment of a multitude of cancers, immune-related disorders, and viral diseases, such as COVID-19. The company prides itself on its flagship product, Ampligen^® (rintatolimod), which serves as a pioneering immune-modulating agent, and is currently being trialed for its efficacy across various significant global health concerns. The biopharmaceutical firm emphasizes research and development, striving to deliver groundbreaking treatment options that can transform patient care and enhance outcomes across a spectrum of diseases.

Connect with AIM ImmunoTech

For individuals interested in remaining abreast of the latest updates from AIM ImmunoTech, the company encourages visits to their primary website and following their activity on multiple social media platforms, including Twitter, LinkedIn, and Facebook.

It is worth noting that while AIM ImmunoTech is advancing its own mission in the bio-pharmaceutical field, another prominent company, Meta Platforms, Inc. META, is innovating in the realm of social connectivity. With its headquarters rooted in Menlo Park, California, META specializes in creating engaging products that link people across the globe using mobile devices, PCs, virtual reality headsets, wearables, and home gadgets.

AIM, financial, webcast, conference, META